Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers

Summary

The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.

Timeline

Start

2015-01-04

Primary completion

2016-07-15

Completion

2016-07-15

Outcome

Met primary endpoint

registry analysis (superiority test); Secukinumab vs Placebo; p = 0.0055; Mean Difference (Net) -18.3 (95% CI -31.01 to -5.59); ANCOVA NCT02362789 ↗

Drugs

Indications